전일 마감가:
$141.16
열려 있는:
$140.99
하루 거래량:
676.07K
Relative Volume:
0.83
시가총액:
$10.53B
수익:
$12.82B
순이익/손실:
$936.34M
주가수익비율:
12.98
EPS:
10.74
순현금흐름:
$1.47B
1주 성능:
-2.78%
1개월 성능:
+1.82%
6개월 성능:
-17.97%
1년 성능:
+1.07%
다비타 Stock (DVA) Company Profile
명칭
Davita Inc
전화
310-536-2668
주소
2000 16TH STREET, DENVER, CO
DVA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
DVA
Davita Inc
|
139.43 | 10.84B | 12.82B | 936.34M | 1.47B | 10.74 |
![]()
HCA
Hca Healthcare Inc
|
364.55 | 91.53B | 71.59B | 5.78B | 4.95B | 22.49 |
![]()
THC
Tenet Healthcare Corp
|
174.65 | 16.51B | 20.52B | 1.46B | 1.41B | 15.12 |
![]()
FMS
Fresenius Medical Care Ag Adr
|
26.29 | 15.93B | 20.92B | 666.06M | 1.85B | 1.1422 |
![]()
EHC
Encompass Health Corp
|
110.00 | 12.06B | 5.51B | 494.70M | 386.40M | 4.84 |
다비타 Stock (DVA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-03-06 | 개시 | Barclays | Equal Weight |
2023-08-07 | 업그레이드 | UBS | Neutral → Buy |
2022-11-01 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2022-10-31 | 다운그레이드 | UBS | Buy → Neutral |
2022-08-19 | 재개 | UBS | Buy |
2022-06-21 | 재확인 | BofA Securities | Underperform |
2021-09-10 | 개시 | Cowen | Market Perform |
2021-08-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2021-03-26 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2021-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
2020-01-24 | 업그레이드 | Goldman | Neutral → Buy |
2019-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2019-10-25 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2019-09-11 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2019-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2019-01-08 | 업그레이드 | UBS | Sell → Neutral |
2019-01-03 | 개시 | Deutsche Bank | Buy |
2018-12-14 | 개시 | Barclays | Overweight |
2018-11-28 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2018-11-16 | 개시 | UBS | Sell |
2018-11-08 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
2018-09-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
2018-01-04 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2017-12-12 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2017-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
2017-12-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2017-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2017-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
2016-12-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
다비타 주식(DVA)의 최신 뉴스
What drives DaVita Inc. stock priceMassive stock growth - PrintWeekIndia
What analysts say about DaVita Inc. stockMarket-crushing stock picks - PrintWeekIndia
Is DaVita Inc. a good long term investmentFree Consultation - jammulinksnews.com
DaVita Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Lobbying Update: $90,000 of DAVITA INC. lobbying was just disclosed - Quiver Quantitative
DaVita’s Quarterly Earnings Preview: What You Need to Know - MSN
DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call - Kilgore News Herald
DaVita Amends Credit Agreement with $250M Loan - TipRanks
Allen learns about dialysis legislation - Statesboro Herald
DaVita Inc. (NYSE:DVA) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
DaVita Inc. Q2 2025 Earnings Preview: What to ExpectNews and Statistics - IndexBox
DaVita’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
DaVita Healthcare (DVA): Riding Out the Storm with Undervalued Potential - AInvest
DaVita HealthCare (DVA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
What makes DaVita Inc. stock price move sharplyChart Breakout Alert - beatles.ru
DaVita Inc. (DVA) Stock Analysis: Unpacking the Impressive 54.79% Return on Equity and Its Implications for Investors - DirectorsTalk Interviews
DaVita's ESG Leadership: A Catalyst for Valuation Uplift in Healthcare - AInvest
DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report - Yahoo Finance
12 Best Stocks to Invest In for Good Returns - Insider Monkey
DaVita Inc (DVA:UN): Stock Price, Quote and News - BNN Bloomberg
Barclays Keeps Their Hold Rating on DaVita (DVA) - The Globe and Mail
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock - Yahoo Finance
DaVita HealthCare (DVA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
DaVita’s SWOT analysis: dialysis provider’s stock faces volume challenges - Investing.com
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant - TradingView
Day in the Life: Jena, DaVita Social Worker - CSRwire
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term - Yahoo Finance
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
DaVita Inc. (DVA) Is Down 9% This Year. Here Is Why - MSN
Is DaVita Stock Underperforming The S&P 500? - Barchart.com
DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship - CSRwire
Bernstein Adjusts Price Target on DaVita to $150 From $184, Maintains Market Perform Rating - MarketScreener
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Government Contract Update: $206M payment to DAVITA INC - Quiver Quantitative
DaVita to offer $750M of senior notes in private offering - MSN
DaVita Inc. (NYSE:DVA) Shares Sold by Two Sigma Investments LP - Defense World
Winners And Losers Of Q1: DaVita (NYSE:DVA) Vs The Rest Of The Outpatient & Specialty Care Stocks - FinancialContent
Those who invested in DaVita (NYSE:DVA) five years ago are up 76% - simplywall.st
DaVita HealthCare (DVA) Down 3.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
DaVita Inc. (DVA) Announces Results of 2025 Annual Meeting of St - GuruFocus
다비타 (DVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):